WO1988002629A1 - 2',3'-didesoxyadenosine composition - Google Patents

2',3'-didesoxyadenosine composition Download PDF

Info

Publication number
WO1988002629A1
WO1988002629A1 PCT/US1987/002530 US8702530W WO8802629A1 WO 1988002629 A1 WO1988002629 A1 WO 1988002629A1 US 8702530 W US8702530 W US 8702530W WO 8802629 A1 WO8802629 A1 WO 8802629A1
Authority
WO
WIPO (PCT)
Prior art keywords
didesoxyadenosine
pharmaceutical composition
component
plurality
dosage
Prior art date
Application number
PCT/US1987/002530
Other languages
French (fr)
Inventor
Phillip Frost
Charles H. Hsiao
Original Assignee
American Health Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US91935886A priority Critical
Priority to US919,358 priority
Priority to US2511887A priority
Priority to US025,118 priority
Application filed by American Health Products Corporation filed Critical American Health Products Corporation
Publication of WO1988002629A1 publication Critical patent/WO1988002629A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

A pharmaceutical composition for the oral treatment of acquired immune deficiency syndrome which comprises a plurality of dosage subunits each having at least two components including a component of 2',3'-didesosxyadenosine and an outer pharmaceutically inert component stable in acidic pH which dissolves in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2',3'-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine.

Description

2* 3'-DIDESOXYADENOSINE COMPOSITION

BACKGROUND OF THE INVENTION This invention relates to pharmaceutical composition useful in the oral treatment of Acquired Immune Deficienc Syndrome.

2 ' , 3 ' -didesoxyadenosine is a known compound Methylmethacrylates are known as coatings fo pharmaceuticals, including Eudragit polymers of Roh Pharma. Hydroxypropylmethylcellulose is known as sustained release matrix, as disclosed first by Christenso et al., U.S. Patent 3,065,143 and again by Schor et al. U.S. Patent 4,389,393.

DESCRIPTION OF THE INVENTION In accordance with a first aspect of the presen invention there is provided a pharmaceutical compositio for the treatment of acquired immune deficiency syndrom which comprises a plurality of dosage subunits each havin at least two components including a component of 2 • ,3 ' didesoxyadenosine and an outer pharmaceutically iner component stable in acidic pH which dissolves in a basi pH, whereby upon oral administration of said pharmaceutica composition the 2' ,3 '-didesoxyadenosine is not exposed t gastrointestinal fluids until the small intestine. Acquired immune deficiency syndrome was found by a prio researcher to be treated in vitro, but not in vivo, wit 2 ', 3 '-didesoxyadenosine. According to the presen invention, the 2' ,3 '-didesoxyadenosine is permitted to remain free of degradation that apparently takes place in the stomach fluids by blocking contact of the 2',3'- didesoxyadenosine with the stomach fluids through said outer pharmaceutically inert component stable in acidic pH.

In a preferred aspect, there is provided a plurality of dosage subunits each having at least three components including a component of 2' ,3 '-didesoxyadenosine sandwiched between pharmaceutically inert layers, at least the outer one of which is stable in acidic pH and which dissolves in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2',3*-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine. As an inner layer remote from the gastrointestinal fluids may be mentioned a nonpareil seed. In a still further embodiment of this aspect of the invention there is provided a capsule containing said plurality of dosage subunits. As an alternative embodiment, there is provided a compressed tablet containing said plurality of dosage subunits, the matrix of said tablet disintegrating in the gastrointestinal tract to yield said plurality of dosage subunits.

In accordance with a second aspect of the present invention there is provided a pharmaceutical composition for the oral treatment of acquired immune deficiency syndrome which comprises a component of 2 ',3'- didesoxyadenosine and a barrier component to shield the 2* ,3 *-didesoxyadenosine from the gastrointestinal fluids until said pharmaceutical composition passes into the small intestine, said barrier component being substantially impervious to degradation in a fluid other than a basic medium, whereby upon introduction into the gastrointestinal tract beyond the stomach said 2' ,3'-didesoxyadenosine is released.

In a third aspect of the present invention there is provided a sustained release composition for the introduction of 2 ', 3 ' -didesoxyadenosine into the bloodstream of a patient suffering from acquired immune deficiency syndrome over a period of at least eight hours which comprises a plurality of dosage subunits each having at least two components including a component of 2' ,3'- didesoxyadenosine and an outer pharmaceutically inert component stable in acidic pH which dissolves in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2' ,3'-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine, said dosage subunits releasing said 2 ' ,3 '-didesoxyadenosine only over a prolonged period of time.

In accordance with this third aspect of the present invention there is provided a sustained release composition for the introduction of 2' ,3'-didesoxyadenosine into the bloodstream of a patient suffering from acquired immune deficiency syndrome over a period of at least eight hours which comprises a plurality of dosage subunits each having at least two components including a component of 2' ,3'- didesoxyadenosine and an outer pharmaceutically inert component stable in acidic pH which only erodes in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2' ,3 '-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine, at least some of said dosage subunits including an outer core of a slowly erodible polymeric material, whereby a sustained release of 2',3'-didesoxyadenosine is achieved.

In an alternate embodiment, there is provided a sustained release composition for the introduction of 2',3'- didesoxyadenosine into the bloodstream of a patient suffering from acquired immune deficiency syndrome over a period of at least eight hours which comprises a plurality of dosage subunits each having at least two components including a component of 2' ,3 '-didesoxyadenosine and an outer pharmaceutically inert component stable in acidic pH which dissolves in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2' ,3 '-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine, said dosage subunits being contained in a matrix of a polymer which only gradually exposes said dosage subunits to the environment of the gastrointestinal tract. In one embodiment, the polymer is a hydroxypropylmethylcellulose, with a tablet made up of from about 60 to 95 percent, and preferably 80 to 92 percent by weight of said dosage subunits and from about 5 to about 40 percent, and preferably from about 8 to about 20 percent of the hydroxypropylmethyl-cellulose. As a hydroxypropylmethylcellulose suitable for the present invention may be mentioned Methocel K15M (Dow Chemical Co., Midland, Michigan) and Methocel K4M (Dow Chemical Co., Midland, Michigan) .

A total adult daily dosage which is spread out over three to five administrations per day, or twice daily in the sustained release aspect of the present invention, comprises from about 2 to about 1O00 mg per day, preferably about 25 to about 750 mg per day, and still more preferably about 10 to 250 mg per administration.

EXAMPLE I Nonpareil seeds (20 to 30 mesh) are wetted with polyvinylpyrrolidone solution using Kollidon 30 (BASF, mw 30,000) which has been first dissolved in isopropanol in a coating pan with repeated dustings of 2' ,3'- didesoxyadenosine (about ten to twenty times) to build up a 2 ' ,3'-didesoxyadenosine-coated nonpareil seed.

EXAMPLE II

Alcohol dissolved Kollidone 90 (BASF, mw 90,000) is used as a wetting agent for nonpareil seeds (20 to 30 mesh) in a coating pan with repeated dustings of 2 ' ,3'- didesoxyadenosine (about ten to twenty times) to build up a

2' ,3 '-didesoxyadenosine-coated nonpareil seed.

EXAMPLE III The 2' ,3 '-didesoxyadenosine-coated nonpareil seeds of Example I are introduced into a Wurster column (Glatt) and coated with a methylmethacrylate in a solvent, using 50 gm Eudrigit L (Rohm Phar a) in a solvent mixture of 250 cc acetone and 250 cc isopropanol. After coating in the Wurster column, the total weight of 2' ,3'-didesoxyadenosine as a percentage of 2',3 '-didesoxyadenosine plus coating is 45%. The dosage subunits dissolve readily in the small intestine.

EXAMPLE IV 2',3 '-Didesoxyadenosine-coated nonpareil seeds of Example I are introduced into a Wurster column (Glatt) and coated with a methylmethacrylate in a solvent, using 25 gm Eudrigit L (Rohm Pharma) , 25 gm Eudragit RS (Rohm Pharma) in a solvent mixture of 250 cc acetone and 250 cc isopropanol. After coating in the Wurster column, the total weight of 2 ',3 '-didesoxyadenosine as a percentage of 2 ',3'-didesoxyadenosine plus coating is 45%. The inclusion of the Eudrigit RS retards dissolution of the dosage subunits to permit a sustained delivery of the 2 ',3'- didesoxyadenosine into the bloodstream of the patient. EXAMPLE V

Capsules are made of a plurality of dosage subunits of Example III to make up 250 mg 2 ' ,3 '-didesoxyadenosine per capsule. The capsules dissolve in the gastrointestinal tract upon oral administration, and each of the dosage subunits releases 2 ',3 '-didesoxyadenosine in the small intestine, to provide 2',3'-didesoxyadenosine to the bloodstream.

EXAMPLE VI Sustained release capsules are made of a plurality of dosage subunits of Example IV to make up 250 mg 2 ',3'- didesoxyadenosine per capsule. The capsules dissolve in the gastrointestinal tract upon oral administration, and each of the dosage subunits releases 2',3'- didesoxyadenosine in the small intestine, to provide 2 ',3'- didesoxyadenosine to the bloodstream of the subject.

EXAMPLE VII

Tablets of a total weight of 330 mg are produced by mixing and then compressing together in a ratio of 10:1 of the dosage subunits of Example II and hydroxypropylmethylcellulose (Methocel K15M, Dow Chemical

Co. , Midland Michigan) .

The sustained release tablet of this example provides an advantage over the other dosage forms in that the dosage subunits are only gradually exposed to the environment of the gastrointestinal fluids, whereby 2' ,3'- didesoxyadenosine is introduced into the bloodstream over a prolonged period of time.

Claims

WHAT IS CLAIMED IS:
1. A pharmaceutical composition for the oral treatment of acquired immune deficiency syndrome which comprises a plurality of dosage subunits each having at least two components including a component of 2 ',3'-didesoxyadenosine and an outer pharmaceutically inert component stable in acidic pH which dissolves in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2' ,3 '-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine.
2. A pharmaceutical composition of claim 1 for the oral treatment of acquired immune deficiency syndrome which comprises a plurality of dosage subunits each having at least three components including a component of 2' ,3 '- didesoxyadenosine sandwiched between pharmaceutically inert layers, at least the outer one of which is stable in acidic pH and which dissolves in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2',3 '-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine.
3. A 2* ,3'-didesoxyadenosine pharmaceutical composition of claim 1 for the oral treatment of acquired immune deficiency syndrome which is a capsule containing said plurality of dosage subunits.
4. A pharmaceutical composition of claim l which is a compressed tablet containing said plurality of dosage subunits, the matrix of said tablet disintegrating in the gastrointestinal tract to yield said plurality of dosage subunits.
5. A pharmaceutical composition for the oral treatment of acquired immune deficiency syndrome which comprises a component of 2 ', 3 '-didesoxyadenosine and a barrier component to shield the 2' ,3'-didesoxyadenosine from the gastrointestinal fluids until said pharmaceutical composition passes into the small intestine, said barrier component being substantially impervious to degradation in a fluid other than a basic medium, whereby upon introduction into the gastrointestinal tract beyond the stomach said 2' ,3'-didesoxyadenosine is released.
6. A sustained release composition for the introduction of 2r,3 -didesoxyadenosine into the bloodstream of a patient suffering from acquired immune deficiency syndrome over a period of at least eight hours which comprises a plurality of dosage subunits each having at least two components including a component of 2' ,3 '-didesoxyadenosine and an outer pharmaceutically inert component stable in acidic pH which dissolves in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2' ,3*-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine, said dosage subunits releasing said 2 ',3 '-didesoxyadenosine only over a prolonged period of time.
7. A sustained release composition for the introduction of 2',3 '-didesoxyadenosine into the bloodstream of a patient suffering from acquired immune deficiency syndrome over a period of at least eight hours which comprises a plurality of dosage subunits each having at least two components including a component of 2' ,3 '-didesoxyadenosine and an outer pharmaceutically inert component stable in acidic pH which only erodes in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2' ,3 '-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine, at least some of said dosage subunits including an outer core of a slowly erodible polymeric material, whereby a sustained release of 2* ,3 '-didesoxyadenosine is achieved.
8. A sustained release composition for the introduction of 2',3 '-didesoxyadenosine into the bloodstream of a ' patient suffering from acquired immune deficiency syndrome over a period of at least eight hours which comprises a plurality of dosage subunits each having at least two components including a component of 2' ,3 '-didesoxyadenosine and an outer pharmaceutically inert component stable in acidic pH which dissolves in a basic pH, whereby upon oral administration of said pharmaceutical composition the 2',3 '-didesoxyadenosine is not exposed to gastrointestinal fluids until the small intestine, said dosage subunits being contained in a matrix of a polymer which only gradually exposes said dosage subunits to the environment of the gastrointestinal tract.
9. A sustained release composition of claim 8 wherein said polymer is a hydroxypropylmethylcellulose.
PCT/US1987/002530 1986-10-16 1987-10-02 2',3'-didesoxyadenosine composition WO1988002629A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US91935886A true 1986-10-16 1986-10-16
US919,358 1986-10-16
US2511887A true 1987-03-12 1987-03-12
US025,118 1987-03-12

Publications (1)

Publication Number Publication Date
WO1988002629A1 true WO1988002629A1 (en) 1988-04-21

Family

ID=26699316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/002530 WO1988002629A1 (en) 1986-10-16 1987-10-02 2',3'-didesoxyadenosine composition

Country Status (1)

Country Link
WO (1) WO1988002629A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0495270A1 (en) * 1987-09-23 1992-07-22 William Dr. Drell Azaribine composition
EP0524579A1 (en) * 1991-07-22 1993-01-27 Bristol-Myers Squibb Company Improved oral dosing formulations of dideoxy purine nucleosides
EP1079809A1 (en) * 1998-05-22 2001-03-07 Bristol-Myers Squibb Company Enteric coated pharmaceutical composition and method of manufacturing
US6607747B2 (en) 1998-05-22 2003-08-19 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US8337892B1 (en) * 1999-07-26 2012-12-25 Ethypharm Low-dose tablets and preparation method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032562A1 (en) * 1980-01-12 1981-07-29 Dr. Karl Thomae GmbH Dipyridamol retard-forms and process for their preparation
WO1984002843A1 (en) * 1983-01-26 1984-08-02 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
EP0136464A2 (en) * 1983-08-24 1985-04-10 BIORESEARCH S.p.A. Therapeutic compositions for oral use containing stable S-Adenosy1-L-Methionine salts
EP0206497A2 (en) * 1985-05-15 1986-12-30 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032562A1 (en) * 1980-01-12 1981-07-29 Dr. Karl Thomae GmbH Dipyridamol retard-forms and process for their preparation
WO1984002843A1 (en) * 1983-01-26 1984-08-02 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
EP0136464A2 (en) * 1983-08-24 1985-04-10 BIORESEARCH S.p.A. Therapeutic compositions for oral use containing stable S-Adenosy1-L-Methionine salts
EP0206497A2 (en) * 1985-05-15 1986-12-30 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0495270A1 (en) * 1987-09-23 1992-07-22 William Dr. Drell Azaribine composition
EP0524579A1 (en) * 1991-07-22 1993-01-27 Bristol-Myers Squibb Company Improved oral dosing formulations of dideoxy purine nucleosides
US5880106A (en) * 1991-07-22 1999-03-09 Bristol-Myers Squibb Company Oral dosing formulations of dideoxy purine nucleosides
EP1079809A1 (en) * 1998-05-22 2001-03-07 Bristol-Myers Squibb Company Enteric coated pharmaceutical composition and method of manufacturing
EP1079809A4 (en) * 1998-05-22 2001-11-07 Squibb Bristol Myers Co Enteric coated pharmaceutical composition and method of manufacturing
US6607747B2 (en) 1998-05-22 2003-08-19 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
JP2006022115A (en) * 1998-05-22 2006-01-26 Bristol Myers Squibb Co Method for producing enteric coating medicinal composition
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
CZ300497B6 (en) * 1998-05-22 2009-06-03 Bristol-Myers Squibb Company Pharmaceutical composition, its spheroized core and process for preparing cores and pharmaceutical composition
US8337892B1 (en) * 1999-07-26 2012-12-25 Ethypharm Low-dose tablets and preparation method

Similar Documents

Publication Publication Date Title
CA1339072C (en) Pharmaceutical formulation as well as a process for its preparation
US5407686A (en) Sustained release composition for oral administration of active ingredient
EP0797435B1 (en) Controlled release matrix for pharmaceuticals
US6930129B2 (en) Methods and devices for providing prolonged drug therapy
KR950002147B1 (en) Pharmaceutical preparations with extended release
AU2005247019B2 (en) Multiparticulate modified release composition
AU596183B2 (en) Controlled release bases for pharmaceuticals
DE69524214T3 (en) Azithromycin-containing arzneiver-submitted forms with a controlled active ingredients
RU2179017C2 (en) Pharmaceutical composition for sustained-release of active substances (variants) and method of its preparing (variants)
EP2638899B1 (en) Timed, pulsatile release systems
CA2375714C (en) Delayed total release two pulse gastrointestinal drug delivery system
AU639231B2 (en) Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5472704A (en) Pharmaceutical controlled-release composition with bioadhesive properties
EP0591424B1 (en) Extended-release form of diltiazem
DE69728710T2 (en) A pharmaceutical tablet characterized by high volume growth on contact with biological fluids
ES2170136T5 (en) Opioid formulations for the treatment of pain.
EP0640337B1 (en) Controlled release-initiation and controlled release-rate pharmaceutical composition
JP2560019B2 (en) The novel formulations and their preparation controls the release of the active compound
AU615211B2 (en) New pharmaceutical preparation
CA2140254C (en) Controlled release morphine preparation
EP0235718B1 (en) Granule remaining in stomach
US5019398A (en) Pharmaceutical composition providing the sustained-release of valproic acid
ES2256910T3 (en) Oral and stable pharmaceutical composition containing a replaced benzimidazol pyridilsulfinil.
EP0519870B1 (en) New oral diclofenac composition
EP0250267A2 (en) Controlled absorption pharmaceutical composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DK FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE